Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD123+ Acute Myeloid Leukemia”

62 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 62 results

Large-scale testing (Phase 3)Study completedNCT02472145
What this trial is testing

An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Who this might be right for
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC 326
Early research (Phase 1)Ended earlyNCT03672851
What this trial is testing

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia

Who this might be right for
Acute LeukemiaAcute Leukemia in RelapseAcute Myeloid Leukemia+1 more
Second Affiliated Hospital of Xi'an Jiaotong University 2
Early research (Phase 1)UnknownNCT03114670
What this trial is testing

Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT

Who this might be right for
Adult Acute Myeloid Leukemia
Affiliated Hospital to Academy of Military Medical Sciences 20
Early research (Phase 1)WithdrawnNCT05513612
What this trial is testing

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Who this might be right for
Acute Myeloid Leukemia (AML)B-cell Non-Hodgkin's Lymphoma (B-NHL)Multiple Myeloma (MM)+2 more
Shanghai Pudong Hospital
Early research (Phase 1)Looking for participantsNCT06835140
What this trial is testing

CD123-CD16-NK Cells Immunotherapy for AML

Who this might be right for
AML (Acute Myelogenous Leukemia)NK CellCD123+ Acute Myeloid Leukemia
Chunji Gao 9
Early research (Phase 1)Looking for participantsNCT05362773
What this trial is testing

MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Leukemia, Acute MyeloidMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
MacroGenics 130
Testing effectiveness (Phase 2)Ended earlyNCT04342962
What this trial is testing

Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 25
Early research (Phase 1)UnknownNCT03796390
What this trial is testing

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

Who this might be right for
Acute Myelocytic Leukemia
Hebei Senlang Biotechnology Inc., Ltd. 15
Testing effectiveness (Phase 2)Ended earlyNCT06508489
What this trial is testing

Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

Who this might be right for
Acute Myeloid Leukemia
Sanofi 7
Very early researchNot Yet RecruitingNCT07201727
What this trial is testing

CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
AML - Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China 10
Early research (Phase 1)Ended earlyNCT03203369
What this trial is testing

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Cellectis S.A. 1
Testing effectiveness (Phase 2)Ended earlyNCT02992860
What this trial is testing

Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY

Who this might be right for
Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)
GWT-TUD GmbH 25
Early research (Phase 1)Active Not RecruitingNCT05716009
What this trial is testing

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML

Who this might be right for
Acute Myeloid Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 36
Testing effectiveness (Phase 2)UnknownNCT04272125
What this trial is testing

Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
LeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute
Chongqing Precision Biotech Co., Ltd 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT03386513
What this trial is testing

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Who this might be right for
Blastic Plasmacytoid Dendritic Cell NeoplasmMyeloproliferative Neoplasm
AbbVie 179
Testing effectiveness (Phase 2)Looking for participantsNCT06561152
What this trial is testing

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Who this might be right for
Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
Stanford University 20
Very early researchUnknownNCT05574608
What this trial is testing

Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia Recurrent
Affiliated Hospital to Academy of Military Medical Sciences 12
Early research (Phase 1)Looking for participantsNCT05233618
What this trial is testing

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

Who this might be right for
MyelofibrosisChronic Myelomonocytic LeukemiaAcute Myeloid Leukemia
Karen Ballen, MD 44
Very early researchEnded earlyNCT02623582
What this trial is testing

CD123 Redirected Autologous T Cells for AML

Who this might be right for
Relapsed or Refractory Acute Myeloid Leukemia
University of Pennsylvania 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT04086264
What this trial is testing

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
AbbVie 218
Load More Results